252 related articles for article (PubMed ID: 35868319)
1. [A practical approach to guideline-directed pharmacological treatment for heart failure with reduced ejection fraction].
Soltani S; Böhm M; Frey N; Eden M; Abdin A; Bauersachs J
Dtsch Med Wochenschr; 2022 Jul; 147(14):931-938. PubMed ID: 35868319
[TBL] [Abstract][Full Text] [Related]
2. Physician perceptions, attitudes, and strategies towards implementing guideline-directed medical therapy in heart failure with reduced ejection fraction. A survey of the Heart Failure Association of the ESC and the ESC Council for Cardiology Practice.
Savarese G; Lindberg F; Christodorescu RM; Ferrini M; Kumler T; Toutoutzas K; Dattilo G; Bayes-Genis A; Moura B; Amir O; Petrie MC; Seferovic P; Chioncel O; Metra M; Coats AJS; Rosano GMC
Eur J Heart Fail; 2024 Jun; 26(6):1408-1418. PubMed ID: 38515385
[TBL] [Abstract][Full Text] [Related]
3. Guideline-directed medical therapy for HFrEF: sequencing strategies and barriers for life-saving drug therapy.
Malgie J; Clephas PRD; Brunner-La Rocca HP; de Boer RA; Brugts JJ
Heart Fail Rev; 2023 Sep; 28(5):1221-1234. PubMed ID: 37311917
[TBL] [Abstract][Full Text] [Related]
4. Prevention of sudden death in heart failure with reduced ejection fraction: do we still need an implantable cardioverter-defibrillator for primary prevention?
Abdelhamid M; Rosano G; Metra M; Adamopoulos S; Böhm M; Chioncel O; Filippatos G; Jankowska EA; Lopatin Y; Lund L; Milicic D; Moura B; Ben Gal T; Ristic A; Rakisheva A; Savarese G; Mullens W; Piepoli M; Bayes-Genis A; Thum T; Anker SD; Seferovic P; Coats AJS
Eur J Heart Fail; 2022 Sep; 24(9):1460-1466. PubMed ID: 35753058
[TBL] [Abstract][Full Text] [Related]
5. Estimating lifetime benefits of comprehensive disease-modifying pharmacological therapies in patients with heart failure with reduced ejection fraction: a comparative analysis of three randomised controlled trials.
Vaduganathan M; Claggett BL; Jhund PS; Cunningham JW; Pedro Ferreira J; Zannad F; Packer M; Fonarow GC; McMurray JJV; Solomon SD
Lancet; 2020 Jul; 396(10244):121-128. PubMed ID: 32446323
[TBL] [Abstract][Full Text] [Related]
6. Adherence to Treatment Guidelines in Ambulatory Heart Failure Patients with Reduced Ejection Fraction in a Latin-American Country: Observational Study of the Colombian Heart Failure Registry (RECOLFACA).
Rivera-Toquica A; Echeverría LE; Arias-Barrera CA; Mendoza-Beltrán F; Hoyos-Ballesteros DH; Plata-Mosquera CA; Ortega-Madariaga JC; Carvajal-Estupiñán JF; Quintero-Yepes V; Zárate-Correa LC; García-Peña ÁA; Velásquez-López N; Anchique CV; Saldarriaga CI; Gómez-Mesa JE
Cardiology; 2024; 149(3):228-236. PubMed ID: 38359813
[TBL] [Abstract][Full Text] [Related]
7. [European guidelines on heart failure: pharmacotherapy].
Grundmann S; von Zur Mühlen C
Herz; 2023 Mar; 48(2):89-94. PubMed ID: 36695878
[TBL] [Abstract][Full Text] [Related]
8. Variation in use and dosing escalation of renin angiotensin system, mineralocorticoid receptor antagonist, angiotensin receptor neprilysin inhibitor and beta-blocker therapies in heart failure and reduced ejection fraction: Association of comorbidities.
Albert NM; Tyson RJ; Hill CL; DeVore AD; Spertus JA; Duffy C; Butler J; Patterson JH; Hernandez AF; Williams FB; Thomas L; Fonarow GC
Am Heart J; 2021 May; 235():82-96. PubMed ID: 33497697
[TBL] [Abstract][Full Text] [Related]
9. Cost-Effectiveness of Quadruple Therapy in Management of Heart Failure With Reduced Ejection Fraction in the United States.
Yan BW; Spahillari A; Pandya A
Circ Cardiovasc Qual Outcomes; 2023 Jun; 16(6):e009793. PubMed ID: 37278232
[TBL] [Abstract][Full Text] [Related]
10. Renal effects of guideline-directed medical therapies in heart failure: a consensus document from the Heart Failure Association of the European Society of Cardiology.
Mullens W; Martens P; Testani JM; Tang WHW; Skouri H; Verbrugge FH; Fudim M; Iacoviello M; Franke J; Flammer AJ; Palazzuoli A; Barragan PM; Thum T; Marcos MC; Miró Ò; Rossignol P; Metra M; Lassus J; Orso F; Jankowska EA; Chioncel O; Milicic D; Hill L; Seferovic P; Rosano G; Coats A; Damman K
Eur J Heart Fail; 2022 Apr; 24(4):603-619. PubMed ID: 35239201
[TBL] [Abstract][Full Text] [Related]
11. Pharmacotherapies in Heart Failure With Preserved Ejection Fraction: A Systematic Review and Network Meta-Analysis.
Sreenivasan J; Malik A; Khan MS; Lloji A; Hooda U; Aronow WS; Lanier GM; Pan S; Greene SJ; Murad MH; Michos ED; Cooper HA; Gass A; Gupta R; Desai NR; Mentz RJ; Frishman WH; Panza JA
Cardiol Rev; 2024 Mar-Apr 01; 32(2):114-123. PubMed ID: 36576372
[TBL] [Abstract][Full Text] [Related]
12. Medical Therapy During Hospitalization for Heart Failure With Reduced Ejection Fraction: The VICTORIA Registry.
Greene SJ; Ezekowitz JA; Anstrom KJ; Demyanenko V; Givertz MM; Piña IL; O'Connor CM; Koglin J; Roessig L; Hernandez AF; Armstrong PW; Mentz RJ
J Card Fail; 2022 Jul; 28(7):1063-1077. PubMed ID: 35301107
[TBL] [Abstract][Full Text] [Related]
13. Medical Therapy for Heart Failure With Reduced Ejection Fraction: The CHAMP-HF Registry.
Greene SJ; Butler J; Albert NM; DeVore AD; Sharma PP; Duffy CI; Hill CL; McCague K; Mi X; Patterson JH; Spertus JA; Thomas L; Williams FB; Hernandez AF; Fonarow GC
J Am Coll Cardiol; 2018 Jul; 72(4):351-366. PubMed ID: 30025570
[TBL] [Abstract][Full Text] [Related]
14. A Systematic Review and Network Meta-Analysis of Pharmacological Treatment of Heart Failure With Reduced Ejection Fraction.
Tromp J; Ouwerkerk W; van Veldhuisen DJ; Hillege HL; Richards AM; van der Meer P; Anand IS; Lam CSP; Voors AA
JACC Heart Fail; 2022 Feb; 10(2):73-84. PubMed ID: 34895860
[TBL] [Abstract][Full Text] [Related]
15. Estimated 5-Year Number Needed to Treat to Prevent Cardiovascular Death or Heart Failure Hospitalization With Angiotensin Receptor-Neprilysin Inhibition vs Standard Therapy for Patients With Heart Failure With Reduced Ejection Fraction: An Analysis of Data From the PARADIGM-HF Trial.
Srivastava PK; Claggett BL; Solomon SD; McMurray JJV; Packer M; Zile MR; Desai AS; Rouleau JL; Swedberg K; Fonarow GC
JAMA Cardiol; 2018 Dec; 3(12):1226-1231. PubMed ID: 30484837
[TBL] [Abstract][Full Text] [Related]
16. Optimal Pharmacologic Treatment of Heart Failure With Preserved and Mildly Reduced Ejection Fraction: A Meta-analysis.
Xiang B; Zhang R; Wu X; Zhou X
JAMA Netw Open; 2022 Sep; 5(9):e2231963. PubMed ID: 36125813
[TBL] [Abstract][Full Text] [Related]
17. Blood pressure in heart failure management and prevention.
Maeda D; Dotare T; Matsue Y; Teramoto K; Sunayama T; Tromp J; Minamino T
Hypertens Res; 2023 Apr; 46(4):817-833. PubMed ID: 36604473
[TBL] [Abstract][Full Text] [Related]
18. Gap between guidelines and clinical practice in heart failure with reduced ejection fraction: Results from TSOC-HFrEF registry.
Chang HY; Wang CC; Wei J; Chang CY; Chuang YC; Huang CL; Chong E; Lin JL; Mar GY; Chan KC; Kuo JY; Wang JH; Chen ZC; Tseng WK; Cherng WJ; Yin WH
J Chin Med Assoc; 2017 Dec; 80(12):750-757. PubMed ID: 29033112
[TBL] [Abstract][Full Text] [Related]
19. Prevalence of heart failure phenotypes and current use of therapies in primary care: results from a nationwide study.
Jensen J; Poulsen MK; Petersen PW; Gerdes B; Rossing K; Schou M
ESC Heart Fail; 2023 Jun; 10(3):1745-1756. PubMed ID: 36852608
[TBL] [Abstract][Full Text] [Related]
20. Sex differences in efficacy of pharmacological therapies in heart failure with reduced ejection fraction: a meta-analysis.
Danielson C; Lileikyte G; Ouwerkerk W; S P Lam C; Erlinge D; Teng TK
ESC Heart Fail; 2022 Aug; 9(4):2753-2761. PubMed ID: 35603531
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
